This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Temas Resources confirms significant gallium and scandium at La Blache
Temas Resources’ latest assays show the La Blache project in Quebec is a genuine multi-metal, multi-revenue…
- Colin Sandell-Hay
- 2 mins
- 12 March 2026 16:18 (AEDT)
GoldArc Resources begins major drilling campaigns at Leonora South
GoldArc is running RC and AC drilling programs in tandem at Leonora South in Western Australia…
- Colin Sandell-Hay
- 2 mins
- 12 March 2026 15:28 (AEDT)
The ASX Today: Relative calm didn’t last long as Brent back to US$100/bbl; March RBA hike priced in?
Greetings and welcome to HotCopper’s the ASX Today, I’m Jon Davidson and after an attack on a Thai cargo ship in the Strait of Hormuz
- Jonathon Davidson
- 3 mins
- 12 March 2026 14:36 (AEDT)
Magnum Mining and Exploration ramping up exploration at Parker project
Magnum Mining and Exploration is preparing for drilling at the Parker project in Arizona on the…
- Colin Sandell-Hay
- 2 mins
- 12 March 2026 14:41 (AEDT)
